



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 11 NOV 2003

WIPO

PCT

SE/03/1596

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed


Dated 7 October 2003

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

0223712.1

Patents Form 1/77

Patents Act 1977
(Rule 16)14 OCT 02 E755295-1, D02934
P01/77 0.00-023

1777

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

100854

2. Patent application number

(The Patent Office will fill in this part)

0223712.1

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB
S-161 85 Söderälje
Sweden

Patents ADP number (if you know it)

7822448003

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

CHEMICAL INTERMEDIATE

5. Name of your agent (if you have one)

Thomas Miller

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TG

Patents ADP number (if you know it)

7822471002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if
 a) any applicant named in part 5 is not an inventor, or
 b) there is an inventor who is not named as an applicant, or
 c) any named applicant is a corporate body.
 See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document.

Continuation sheets of this form

Description	15
Claim(s)	04
Abstract	01

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 5/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (Please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Authorised Signatory

Date

14/10/2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer C Bennett - 01625 230148

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

100854

- 1 -

CHEMICAL INTERMEDIATE**Field of the Invention**

5 This invention relates to novel intermediates and their use in a process for the preparation of oxabispidine compounds.

Background to the Invention

10 The number of documented compounds including the 9-oxa-3,7-diazabicyclo-[3.3.1]nonane (oxabispidine) structure is very few. As a result, there are very few known processes that are specifically adapted for the preparation of oxabispidine compounds.

15 Certain oxabispidine compounds are disclosed in *Chem. Ber.* 96(11), 2827 (1963) as intermediates in the synthesis of 1,3-daza-6-oxa-adamantanes.

20 Hemiacetals (and related compounds) having the oxabispidine ring structure are disclosed in *J. Org. Chem.* 31, 277 (1966), *ibid.* 61(25); 8897 (1996), *ibid.* 63(5), 1566 (1998) and *ibid.* 64(3), 960 (1999) as unexpected products from the oxidation of 1,5-diazacyclooctane-1,3-diols or the reduction of 1,5-diazacyclooctane-1,3-diones.

25 1,3-Dimethyl-3,7-ditosyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane is disclosed in *J. Org. Chem.* 32, 2425 (1967) as a product from the attempted acetylation of *trans*-1,3-dimethyl-1,5-ditosyl-1,5-diazacyclooctane-1,3-diol.

25


International patent application WO 01/28992 describes the synthesis of a wide range of oxabispidine compounds, which compounds are indicated as being useful in the treatment of cardiac arrhythmias. Amongst the compounds disclosed are a number that bear a *N*-2-(*tert*-butoxycarbonylamino)ethyl substituent.

30

Co-pending International Application no. PCT/SE02/00727 discloses *inter alia* a process for the preparation of a compound of formula I,


100854

- 2 -



wherein R¹ represents H or an amino protective group and R² represents C₁₋₆ alkyl (optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro and aryl) or aryl, wherein each aryl and aryloxy group, unless otherwise specified, is 5 optionally substituted;


which process comprises reaction of a compound of formula II,



II

wherein R¹ is as defined above, with either:


(i) a compound of formula III,



10

wherein R¹⁶ represents unsubstituted C₁₋₄ alkyl, C₁₋₄ perfluoroalkyl or phenyl, which latter group is optionally substituted by one or more substituents selected from C₁₋₆ alkyl, halo, nitro and C₁₋₆ alkoxy, and R² is as defined above; or

(ii) acrylamide, followed by reaction of the resulting intermediate of formula IV,



IV

15

wherein R¹ is as defined above, with an alcohol of formula R²-OH and an agent that promotes, or agents that in combination promote, rearrangement and oxidation of the compound of formula IV to an intermediate isocyanate, which may then react with the alcohol of formula R²-OH, wherein R² is as defined above.

20


- 3 -

The above application also discloses a process for the preparation of a compound of formula I in which R¹ represents H, which comprises the preparation of a corresponding compound of formula I in which R¹ represents an amino protective group by processes described therein, followed by removal of the amino protective group from that compound. It also discloses in 5 Example 3 Alternative II that [2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]-non-3-yl)ethyl]carbamic acid *tert*-butyl ester 2,4,6-trimethylbenzenesulfonic acid salt was converted into the free base with aqueous sodium hydroxide. The [2-(7-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]carbamic acid *tert*-butyl ester obtained was hydrogenated 10 in the presence of citric acid and 5% Pd/C to give [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]carbamic acid *tert*-butyl ester which was reacted directly without further purification to give (2-{7-[3-(4-cyanoanilino)propyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}-ethyl)carbamic acid *tert*-butyl ester.

Certain novel solid salts of have now been found which offer advantages over known 15 methods.

Description of the Invention


According to a first aspect of the invention there is provided acid addition salts of 20 compounds of Formula I



wherein R² represents C₁₋₆ alkyl (optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro and aryl) or aryl, wherein each aryl and aryloxy group, unless otherwise specified, is optionally substituted.

25

In a first aspect the acid component of the acid addition salt is represented by formula A



100854

- 4 -

wherein R^{16} represents unsubstituted C_{1-4} alkyl, C_{1-4} perfluoroalkyl or phenyl, which latter group is optionally substituted by one or more substituents selected from C_{1-6} alkyl, halo, nitro and C_{1-6} alkoxy, and R^2 is as defined above. Specific salts that may be mentioned include toluenesulfonate, benzenesulfonate, nosylate, brosylate, besylate and mesitylate.


5

In one aspect the salts are in solid form.

In another aspect the salt is [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester 2,4,6-trimethylbenzenesulfonic acid.


10

In a further aspect the present invention provides a process for the preparation of a compound of Formula II



II

15 wherein R^1 represents a structural fragment of formula Ia



in which A represents CH_2 and R^3 represents $-OH$ or $-N(H)R^7$;

R^4 represents H, C_{1-6} alkyl or, together with R^3 , represents $=O$;

20 R^5 represents phenyl or pyridyl, both of which groups are optionally substituted by one or more substituents selected from $-OH$, cyano, halo, nitro, C_{1-6} alkyl (optionally terminated by $-N(H)C(O)OR^{13a}$), C_{1-6} alkoxy, $-N(R^{14a})R^{14b}$, $-C(O)R^{14c}$, $-C(O)OR^{14d}$, $-C(O)N(R^{14e})R^{14f}$, $-N(R^{14g})C(O)R^{14h}$, $-N(R^{14i})C(O)N(R^{14j})R^{14k}$, $-N(R^{14m})S(O)_2R^{13b}$, $-S(O)_2R^{13c}$ and/or

25 $-OS(O)_2R^{13d}$;

R^7 represents H, C_{1-6} alkyl, $-B-aryl$, $-B-Het^1$, $-C(O)R^{9a}$, $-C(O)OR^{9b}$, $-S(O)_2R^{9c}$, $-[C(O)]_pN(R^{10a})R^{10b}$ or $-C(NH)NH_2$;

- 5 -

R^{9a} to R^{9d} independently represent, at each occurrence when used herein, C_{1-6} alkyl (optionally substituted and/or terminated by one or more substituents selected from halo, aryl and Het^2), aryl, Het^3 , or R^{9a} and R^{9d} independently represent H;

R^{10a} and R^{10b} independently represent, at each occurrence when used herein, H or C_{1-6} alkyl

5 (optionally substituted and/or terminated by one or more substituents selected from halo, aryl and Het^4), aryl, Het^5 , or together represent C_{3-6} alkylene, optionally interrupted by an O atom; E represents, at each occurrence when used herein, a direct bond or C_{1-4} alkylene;

B represents -Z-, -Z-N(R^{12})-, -N(R^{12})-Z-, -Z-S(O)_n- or -Z-O- (in which latter two groups, Z is

10 attached to the carbon atom bearing R^3 and R^4);

Z represents a direct bond or C_{1-4} alkylene;

R^{11} and R^{12} independently represent H or C_{1-6} alkyl;

R^{13a} to R^{13d} independently represent C_{1-6} alkyl;

R^{14a} and R^{14b} independently represent H, C_{1-6} alkyl or together represent C_{3-6} alkylene,

15 resulting in a four- to seven-membered nitrogen-containing ring;

R^{14c} to R^{14m} independently represent H or C_{1-6} alkyl; and

n represents 0, 1 or 2;

p represents 1 or 2;

Het^1 to Het^5 independently represent, at each occurrence when used herein, five- to twelve-


20 membered heterocyclic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, which heterocyclic groups are optionally substituted by one or more substituents selected from =O, -OH, cyano, halo, nitro, C_{1-6} alkyl, C_{1-6} alkoxy, aryl, aryloxy, - $N(R^{15a})R^{15b}$, -C(O)R^{15c}, -C(O)OR^{15d}, -C(O)N(R^{15e})R^{15f}, -N(R^{15g})C(O)R^{15h} and - $N(R^{15i})S(O)_2R^{15j}$.

25 R^{15a} to R^{15j} independently represent C_{1-6} alkyl, aryl or R^{15a} to R^{15i} independently represent H; and R^2 represents C_{1-6} alkyl (optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro and aryl) or aryl, wherein each aryl and aryloxy group, unless otherwise specified, is optionally substituted.


100854

- 6 -

wherein a salt of a compound of Formula I



5 in which R² is as previously defined is reacted with a compound of Formula III



wherein Y represents O or N(R⁷) and R⁴, R⁵, R⁷ and B are as hereinbefore defined, at a temperature in the range of 0°C to 100°C for example at elevated temperature (e.g. 60°C to reflux) in the presence of a water and in the presence of a base, for example sodium 10 carbonate.

In a first aspect the salt has been isolated in solid form prior to this process step.

A second aspect comprises a process for the preparation of *tert*-butyl 2-[(2*S*)-3-(4-15 cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-dieaza-bicyclo[3.3.1]-non-3-yl]ethylcarbamate which comprises reacting a salt of [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester with 4-[(2*S*)-oxiranylmethoxy]benzonitrile at a temperature in the range of 0°C to 100°C in the presence of water and in the presence of a base, for example sodium carbonate.

20

In another aspect of the process an isolated salt of [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester is used particularly the 2,4,6-trimethylbenzenesulfonic acid salt.

25 The use of water as the reaction medium in the process has important advantages in terms of waste disposal and consequences for the environment.

100854

- 7 -

The term "aryl", when used herein, includes C₆-10 aryl groups such as phenyl, naphthyl and the like. The term "aryloxy", when used herein includes C₆-10 aryloxy groups such as phenoxy, naphthoxy and the like. For the avoidance of doubt, aryloxy groups referred to herein are attached to the rest of the molecule *via* the O-atom of the oxy-group. Unless

5 otherwise specified, aryl and aryloxy groups may be substituted by one or more substituents including -OH, cyano, halo, nitro, C₁-6 alkyl, C₁-6 alkoxy,

-N(R^{14a})R^{14b}, -C(O)R^{14c}, -C(O)OR^{14d}, -C(O)N(R^{14b})R^{14f}, -N(R^{14g})C(O)R^{14h},

-N(R^{14m})S(O)₂R^{13b}, -S(O)₂R^{13c} and/or -OS(O)₂R^{13d} (wherein R^{13b} to R^{13d} and R^{14a} to R^{14m} are as hereinbefore defined). When substituted, aryl and aryloxy groups are preferably

10 substituted by between one and three substituents.

The term "halo", when used herein, includes fluoro, chloro, bromo and iodo.

Het (Het¹ to Het⁵) groups that may be mentioned include those containing 1 to 4 heteroatoms

15 (selected from the group oxygen, nitrogen and/or sulfur) and in which the total number of atoms in the ring system are between five and twelve. Het (Het¹ to Het⁵) groups may be fully saturated, wholly aromatic, partly aromatic and/or bicyclic in character. Heterocyclic groups that may be mentioned include benzodioxanyl, benzodioxepanyl, benzodioxolyl,

benzofuranyl, benzimidazolyl, benzomorpholinyl, benzoxazinonyl, benzothiophenyl,

20 chromanyl, cinnolinyl, dioxanyl, furanyl, imidazolyl, imidazo[1,2-a]pyridinyl, indolyl, isoquinolinyl, isoxazolyl, morpholinyl, oxazolyl, phthalazinyl, piperazinyl, piperidinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolyl, thienyl, thiochromanyl, triazolyl and the like. Substituents on Het (Het¹ to Het⁵) groups may,

25 where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of Het (Het¹ to Het⁵) groups may be *via* any atom in the ring system including (where appropriate) a heteroatom, or an atom on any fused carbocyclic ring that may be present as part of the ring system. Het (Het¹ to Het⁵) groups may also be in the N- or S-oxidised form.

30

The use of protecting groups is fully described in "Protective Groups in Organic Chemistry", edited by J.W.F. McOmie, Plenum Press (1973), and "Protective Groups in Organic Synthesis", 3rd edition, T.W. Greene & P.G.M. Wutz, Wiley-Interscience (1999).

100854

- 8 -

The process of the invention possesses the surprising advantage that compounds of formula I may be prepared conveniently from solid (as opposed to, for example, oily or semi-solid) precursors, which precursors may be purified using simple procedures (e.g. recrystallisation).

5 Further, the process of the invention may have the advantage that compounds of formula I may be prepared in higher yields, by way of fewer steps, in less time, more conveniently, and at a lower cost, than when prepared according to the process described in international patent application WO 01/28992.

10 The invention is illustrated, but in no way limited, by the following examples.

Examples

General Experimental Procedures

15 Mass spectra were recorded on one of the following instruments: a Waters ZMD single quad with electrospray (S/N mc350); a Perkin-Elmer SciX API 150ex spectrometer; a VG Quattro II triple quadrupole; a VG Platform II single quadrupole; or a Micromass Platform LCZ single quadrupole mass spectrometer (the latter three instruments were equipped with a pneumatically assisted electrospray interface (LC-MS)). ^1H NMR and ^{13}C NMR

20 measurements were performed on Varian 300, 400 and 500 spectrometers, operating at ^1H frequencies of 300, 400 and 500 MHz respectively, and at ^{13}C frequencies of 75.5, 100.6 and 125.7 MHz respectively.

Rotamers may or may not be denoted in spectra depending upon ease of interpretation of spectra.

25 Unless otherwise stated, chemical shifts are given in ppm with the solvent as internal standard.

Abbreviations

API = atmospheric pressure ionisation (in relation to MS)

30 br = broad (in relation to NMR)

d = doublet (in relation to NMR)

dd = doublet of doublets (in relation to NMR)

Et = ethyl

100854

- 9 -

eq.	=	equivalents
GC	=	gas chromatography
h	=	hour(s)
HPLC	=	high performance liquid chromatography
5	IMS	= industrial methylated spirit
IPA	=	<i>iso</i> -propyl alcohol
m	=	multiplet (in relation to NMR)
Me	=	methyl
min.	=	minute(s)
10	m.p.	= melting point
MS	=	mass spectroscopy
Pd/C	=	palladium on carbon
q	=	quartet (in relation to NMR)
rt	=	room temperature
15	s	= singlet (in relation to NMR)
t	=	triplet (in relation to NMR)

Prefixes *n*-, *s*-, *i*-, *t*- and *tert*- have their usual meanings: normal, secondary, *iso*, and tertiary.

20 Example 1

a) [2-(9-Oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester 2,4,6-trimethylbenzenesulfonic acid salt

[2-(7-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester 2,4,6-trimethylbenzenesulfonic acid salt (150 g prepared as described below), 4-methyl-2-pentanol (MIBC) (300 mL) and methanol (300 mL) were combined in a metal hydrogenation vessel. Solid 5% Pd/C catalyst (4.5 g, 61% water wet, Johnson Matthey type 440L) was added. The mixture was then hydrogenated under 2.5 bar of hydrogen pressure and was simultaneously heated to 55°C. Gas uptake measurement showed the reaction to be complete after 2 hours. After cooling to 40°C the catalyst was removed by filtration through a glass fibre filter paper. The catalyst was washed on the filter with MIBC (300 mL) and the washings added to the main filtrate. Solvent (185 mL) was removed by distillation at atmospheric pressure. More solvent (243 mL) was then removed by reduced pressure (<100 mmHg) distillation. Isopropyl ether (IPE) (1050 mL) was added quickly at 70°C, which

- 10 -

caused the temperature to fall to 45°C. An unstirrable precipitate formed in the reaction vessel. The mixture was re-heated and solvent distilled and collected (268 mL). MIBC (150 mL) was added and at 80°C all material dissolved. The ratio of MIBC:IPE was now approximately 4:5. The solution was allowed to cool and was seeded (86 mg) at 70°C. The reaction was left to cool overnight to ambient temperature. The mixture was cooled to 8°C and then the solid product collected by filtration. The solid was washed on the filter with IPE (450 mL) and then sucked dry. Further drying *in vacuo* at 60°C gave the title compound as a white solid (115.0 g, 91%).

m.p. 147-9°C

10

b) Tert-Butyl 2-[7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethylcarbamate

Aqueous sodium carbonate solution (1M, 53 mL) was added to a solution of [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester 2,4,6-15 trimethylbenzenesulfonic acid salt (50.0 g) in water (100 mL). Solid 4-[(2S)-oxiranylmethoxy]benzonitrile (19.1 g) was added and was rinsed into the reaction flask with water (50 mL). The reaction was heated to 75°C for 3 hours and then left to stir at ambient temperature overnight. Toluene (350 mL) was added followed by aqueous sodium hydroxide (2M, 90 mL). The mixture was stirred for 5 minutes and then the phases were separated. The 20 aqueous phase was discarded and the toluene phase washed with aqueous citric acid (10% w/v, 180 mL). The toluene phase was discarded. MIBC (240 mL) and aqueous sodium hydroxide (5M, 180 mL) were added to the citric acid phase. After mixing well the phases were separated and the aqueous discarded. The MIBC was washed with aqueous sodium chloride (20% w/v, 50 mL). The MIBC was concentrated under vacuum at < 55°C. Solvent 25 was collected (water 13 mL, MIBC 29 mL). The MIBC solution was cooled to ambient temperature and filtered, washing through with MIBC (50 mL). Solvent (152 mL) was distilled under vacuum at <66°C and then distillation was stopped. IPE (360 mL) was added causing the temperature to fall from 65°C to 37°C. After stirring for 15 minutes T fell by 2°C to 35°C and crystallisation started. The mixture was left to cool to ambient temperature 30 overnight with stirring. The mixture was cooled to 5°C and the product collected by filtration. The solid was washed on the filter with IPE (150 mL) and sucked dry. Further drying *in vacuo* at 55°C gave the title compound as a white solid (41.2 g, 87%).

- 11 -

Preparation of [2-(7-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethyl]carbamic acid *tert*-butyl ester, 2,4,6-trimethylbenzenesulfonic acid salt

a) 2-(*tert*-Butyloxycarbonylamino)ethyl 2,4,6-trimethylbenzenesulfonate

5 Triethylamine (65 mL, 465.3 mmole, 1.5 eq) was added in one portion to a solution of *tert*-butyl *N*-(2-hydroxyethyl)carbamate (50.11 g, 310.2 mmole, 1.0 eq.) in dichloromethane (250 mL, 5 vols). The solution was cooled to

-10°C and trimethylamine hydrochloride (14.84 g, 155.1 mmole, 0.5 eq.) was added in one portion. The resultant mixture was cooled further to

10 -15°C, stirred for 5 minutes, then treated with a solution of mesitylenesulfonyl chloride (74.74

g, 341.2 mmole, 1.1 eq) in dichloromethane (250 mL, 5 vols), over 28 minutes such that the internal temperature remained below -10°C. Once the addition was complete a precipitate

had formed and the mixture was stirred at -10°C for a further 30 minutes. Water (400 mL, 8 vols) was added and all of the precipitate dissolved. The mixture was stirred rapidly for 5

15 minutes, and then the two layers were separated. A solvent swap from dichloromethane to

IPA was carried out by distillation at reduced pressure. Solvent was removed (450 mL) and replaced with IPA (450 mL) (initial pressure was 450 mbar, b.p. 24°C; final pressure was 110

mbar, b.p. 36 °C). At the end of the distillation, solvent (150 mL) was removed to bring the volume down to 350 mL (7 vols with respect to the amount of *tert*-butyl *N*-(2-

20 hydroxyethyl)carbamate used). The solution was cooled to 25°C, then water (175 mL) was added slowly with stirring, causing the solution gradually to turn cloudy. No solid had precipitated at this stage. More water (125 mL) was added, and a solid precipitate started to form after about 75 mL had been added. The internal temperature rose from 25°C to 31°C.

The mixture was stirred slowly and cooled to 7°C. The solid was collected by filtration,

25 washed with IPA:water (1:1, 150 mL) and dried *in vacuo* at 40°C for 21 hours to give the title compound as a white crystalline solid (92.54 g, 87%).

m.p. 73.5°C

¹H-NMR (300MHz, CDCl₃) δ 1.42 (9H, s), 2.31 (3H, s), 2.62 (6H, s) 3.40 (2H, q), 4.01 (2H, t), 4.83 (1H, bs), 6.98 (2H, s)

100854

- 12 -

b) 3-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane**b (i) *N,N*-Bis(2-oxiranylmethyl)benzenesulfonamide**

Water (2.5 L, 10 vol.) followed by epichlorohydrin (500 mL, 4 eq.) were added to 5 benzenesulfonamide (250 g, 1 eq.). The reactants were heated to 40°C. Aqueous sodium hydroxide (130 g in 275 mL of water) was added such that the temperature of the reaction remained between 40°C and 43°C. This took approximately 2 hours. (The rate of sodium hydroxide addition needs to be slower at the start of the addition than at the end in order to keep within the temperature range stated.) After the addition of sodium hydroxide was

10 complete, the reaction was stirred at 40°C for 2 hours, then at ambient temperature overnight. The excess epichlorohydrin was removed as a water azeotrope by vacuum distillation (ca. 4 kPa (40 mbar), internal temp 30°C), until no more epichlorohydrin distilled.

Dichloromethane (1L) was added and the mixture stirred rapidly for 15 minutes. The phases were allowed to separate (this took 10 minutes although totally clear phases are obtained after 15 standing overnight). The phases were separated and the dichloromethane solution used in the subsequent step below.

¹H NMR (400MHz, CDCl₃): δ 2.55-2.65 (2H, m), 2.79 (2H, t, J 4.4), 3.10-3.22 (4H, m), 3.58-3.73 (2H, m), 7.50-7.56 (2H, m), 7.58-7.63 (1H, m), 7.83-7.87 (2H, m).

20 b (ii) 5-Benzyl-3,7-dihydroxy-1-phenylsulfonyl-1,5-diazacyclooctane

IMS (2.5 L, 10 vol) was added to the dichloromethane solution from step (i) above. The solution was distilled until the internal temperature reached 70°C. Approximately 1250 mL of solvent was collected. More IMS (2.5 L, 10 vol) was added followed by benzylamine (120 mL, 0.7 eq.) in one portion (no exotherm seen), and the reaction was heated at reflux for 6 hours (no change from 2 hour sampling point). More benzylamine was added (15 mL) and the solution was heated for a further 2 hours. The IMS was distilled off (ca. 3.25 L) and toluene was added (2.5 L). More solvent was distilled (ca. 2.4 L) and then further toluene added (1 L). The head temperature was now 110°C. A further 250 mL of solvent was collected at 110°C. Theoretically, this left the product in ca. 2.4 L of toluene at 110°C. This 30 solution was used in the next step.

¹H NMR (400 MHz, CDCl₃): δ 7.83-7.80 (4H, m, ArH), 7.63-7.51 (6H, m, ArH), 7.30-7.21 (10H, ArH), 3.89-3.80 (4H, m, CH(a) +CH(b)), 3.73 (2H, s, CH₂Ph(a)), 3.70 (2H, s, CH₂Ph(b)), 3.59 (2H, dd, CHHNSO₂Ar(a)), 3.54 (2H, dd, CHHNSO₂Ar(b)), 3.40 (2H, dd,

- 13 -

CHHNSO₂Ar(b)), 3.23 (2H, dd, CHHNSO₂Ar(a)), 3.09-2.97 (4H, m, CHHNBn(a) + CHHNBn(b)), 2.83 (2H, dd, CHHNBn(b)), 2.71 (2H, dd, CHHNBn(a))

(Data taken from purified material comprising a 1:1 mixture of *trans*- (a), and *cis*-diol (b))

5 b (iii) 3-Benzyl-7-(phenylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane

The toluene solution from the previous step (ii) above was cooled to 50°C. Anhydrous methanesulfonic acid (0.2 L) was added. This caused a temperature rise from 50°C to 64°C. After 10 minutes, methanesulfonic acid was added (1 L) and the reaction heated to 110°C for 5 hours. Toluene was then distilled from the reaction; 1.23 L was collected. (Note that the 10 internal temperature should not be allowed higher than 110°C at any stage otherwise the yield will be decreased.) The reaction was then cooled to 50°C and a vacuum applied to remove the rest of the toluene. Heating to 110°C and 65 kPa (650 mbar) allowed a further 0.53 L to be removed. (If the toluene can be removed at a lower temperature and pressure then that is beneficial.) The reaction was then left to cool to 30°C and deionised water (250 mL) was 15 added. This caused the temperature to rise from 30°C to 45°C. More water (2.15 L) was added over a total time of 30 minutes such that the temperature was less than 54°C. The solution was cooled to 30°C and then dichloromethane (2 L) was added. With external cooling and rapid stirring, the reaction mixture was basified by adding aqueous sodium hydroxide (10 M, 2 L) at a rate that kept the internal temperature below 38°C. This took 80 20 minutes. The stirring was stopped and the phases separated in 3 minutes. The layers were partitioned. IMS (2 L) was added to the dichloromethane solution and distillation started. Solvent (2.44 L) was collected until the head temperature reached 70°C. Theoretically, this left the product in 1.56 L of IMS. The solution was then allowed to cool to ambient 25 temperature overnight with slow stirring. The solid product that precipitated was filtered and washed with IMS (0.5 L) to give a fawn-coloured product that, on drying at 50°C, in vacuum, gave 50.8 g (8.9% over 3 steps).

20.0 g of this product was dissolved in acetonitrile (100 mL) at reflux to give a pale yellow solution. After cooling to ambient temperature, the crystals that formed were collected by 30 filtration and washed with acetonitrile (100 mL). The product was dried *in vacuo* at 40°C for 1 hour to give 17.5 g (87%) of sub-title compound.

¹H NMR (400 MHz, CDCl₃): δ 7.18-7.23 (10H, m), 3.86-3.84 (2H, m), 3.67 (2H, d), 3.46 (2H, s), 2.91 (2H, d), 2.85 (2H, dd), 2.56 (2H, dd)

- 14 -

b (iv) 3-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane dihydrochloride

Concentrated hydrobromic acid (1.2 L, 3 rel. vol.) was added to solid 3-benzyl-7-

(phenylsulfonyl)-9-oxa-3,7-diazabicyclo[3.3.1]nonane (400 g, see step (iii) above) and the

5 mixture was heated to reflux under a nitrogen atmosphere. The solid dissolved in the acid at 95°C. After heating the reaction for 8 hours, HPLC analysis showed that the reaction was complete. The contents were cooled to room temperature. Toluene (1.2 L, 3 rel. vol.) was added and the mixture stirred vigorously for 15 minutes. Stirring was stopped and the phases were partitioned. The toluene phase was discarded along with a small amount of interfacial 10 material. The acidic phase was returned to the original reaction vessel and sodium hydroxide (10 M, 1.4 L, 3.5 rel. vol.) was added in one portion. The internal temperature rose from 30°C to 80°C. The pH was checked to ensure it was >14. Toluene (1.6L, 4 rel. vol.) was added and the temperature fell from 80°C to 60°C. After vigorous stirring for 30 minutes, the phases 15 were partitioned. The aqueous layer was discarded along with a small amount of interfacial material. The toluene phase was returned to the original reaction vessel, and 2-propanol (4 L, 10 rel. vol.) was added. The temperature was adjusted to between 40°C and 45°C. Concentrated hydrochloric acid (200 mL) was added over 45 minutes such that the temperature remained at between 40°C and 45°C. A white precipitate formed. The mixture was stirred for 30 minutes and then cooled to 7°C. The product was collected by filtration, 20 washed with 2-propanol (0.8 L, 2 rel vol.), dried by suction and then further dried in a vacuum oven at 40°C. Yield = 297 g (91%).

¹H NMR (CD₃OD + 4 drops D₂O): δ 2.70 (br d, 2H), 3.09 (d, 2H), 3.47 (br s, 4H), 3.60 (s, 2H), 4.12 (br s, 2H), 7.30-7.45 (m, 5H).

API MS: *m/z* = 219 [C₁₃H₁₈N₂O+H]⁺.

25

B (v) 3-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane

All volumes and equivalents are measured with respect to the amount of 3-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane dihydrochloride (see step (iv) above) used. Toluene (420 mL, 7 vols) and aqueous sodium hydroxide solution (2M, 420 mL, 7 vols, 4.0 eq) were added to 3-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane dihydrochloride (60.07 g, 206.03 mmole, 1.0 eq., 30 see step (iv) above). The mixture was stirred under nitrogen, heated to 60°C and held at this temperature for 30 minutes by which time two clear layers had formed. The lower, aqueous layer was removed, and the toluene solution of title compound (free base) was azeodried at

100854

- 15 -

atmospheric pressure (total volume of solvent removed = 430 mL; total volume of toluene added = 430 mL), then concentrated to a volume of 240 mL (4 vols). Karl Fischer analysis at this stage showed 0.06% water in the solution. The dried solution of title compound (theoretically 44.98 g, 206.03 mmole, 1.0 eq) was used as such in a subsequent step.

5

c) 2-(7-Benzyl-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethylcarbamic acid *tert*-butyl ester, 2,4,6-trimethylbenzenesulfonic acid salt

A warm (28°C) solution of 2-(*tert*-butyloxycarbonylamino)ethyl 2,4,6-trimethylbenzenesulfonate (70.93 g, 206.03 mmole, 1.0 eq, see Preparation a above) in 10 toluene (240 mL, 4 vols) was added to a solution of 3-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane (44.98 g, 206.03 mmole, 1.0 eq, in toluene (240 mL, 4 vols) (see Preparation b (v) above). The resultant solution was stirred rapidly under nitrogen, with heating at 68°C for 8 hours. The reaction was left to stir at ambient temperature for 84 hours. A thick, white solid precipitate had formed in a pale yellow solution. The mixture was cooled 15 to +9°C, and title compound was collected by filtration. The reaction vessel was washed with toluene (100 mL) and added to the filter. The filter cake was washed with toluene (150 mL). The white solid product was suction dried for 15 minutes, then dried to constant weight *in vacuo* at 40°C for 23 hours. The yield of title compound obtained was 79.61 g, 141.7 mmole, 69%. The combined filtrate and washings (670 mL) were washed with aqueous sodium 20 hydroxide solution (2M, 200 mL, 3.3 vols). The mixture was heated to 60°C, and held at this temperature for 20 minutes with rapid stirring. The two layers were then separated. The toluene solution was concentrated to 200 mL by vacuum distillation (bp 50-54°C at 650-700 mbar; bp 46°C at 120 mbar at the end). As the distillation progressed, the solution became cloudy due to the formation of title compound. It was assumed that 20% of the original 25 amount of 3-benzyl-9-oxa-3,7-diazabicyclo[3.3.1]nonane remained in the filtrate, and so extra 2-(*tert*-butyloxycarbonylamino)ethyl 2,4,6-trimethylbenzenesulfonate (14.20 g, 41.21 mmole, 0.2 eq) was added in one portion (charged as a solid rather than as a solution in toluene). The cloudy solution was heated at 67°C for 8 hours with rapid stirring, and then left to stir at ambient temperature for 11 hours. The mixture was cooled to +8°C, and title compound was 30 collected by filtration. The reaction vessel was washed with more toluene (2 x 30 mL), and added to the filter. The white solid product was suction dried for 15 minutes, then dried to constant weight *in vacuo* at 40°C for 7 hours. The yield of title compound was 23.25 g, 41.39

100854

- 16 -

mmole, 20%. The combined yield of title compound (a white solid) was 102.86 g, 183.11 mmole, 89%.

m.p. 190-190.5°C


¹H-NMR (300MHz, CDCl₃) δ 1.43 (9H, s), 2.17 (3H, s), 2.51 (6H, s), 2.73-2.80 (2H, m),
2.90-2.94 (4H, m), 3.14-3.22 (4H, m), 3.37 (2H, brm), 3.89 (2H, bs), 4.13 (2H, bs), 6.74 (2H, s), 7.12 (1H, bt), 7.42-7.46 (5H, m)

100854

- 17 -


Claims

1. An acid addition salt of a compound of Formula I



5 wherein R² represents C₁₋₆ alkyl (optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro and aryl) or aryl, wherein each aryl and aryloxy group, unless otherwise specified, is optionally substituted.

2. A salt according to claim 1 in which the acid component of the acid addition salt is
10 represented by formula A



wherein R¹⁶ represents unsubstituted C₁₋₄ alkyl, C₁₋₄ perfluoroalkyl or phenyl, which latter group is optionally substituted by one or more substituents selected from C₁₋₆ alkyl, halo, nitro and C₁₋₆ alkoxy, and R² is as defined above.

15

3. A salt according to claim 2 wherein the salt is a toluenesulfonate, benzenesulfonate, nosylate, brosylate, besylate or mesitylate salt.

4. A salt according to any previous claim in which the salt is in solid form.


20

5. A salt according to any previous claim which is [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester 2,4,6-trimethylbenzenesulfonic acid.

100854

- 18 -

6. A process for the preparation of a compound of Formula II

wherein R^1 represents a structural fragment of formula Ia

5

in which A represents CH_2 and R^3 represents $-OH$ or $-N(H)R^7$; R^4 represents H, C_{1-6} alkyl or, together with R^3 , represents $=O$; R^5 represents phenyl or pyridyl, both of which groups are optionally substituted by one or more substituents selected from $-OH$, cyano, halo, nitro, C_{1-6} alkyl (optionally terminated by -

10 $N(H)C(O)OR^{13a}$), C_{1-6} alkoxy,
 $-N(R^{14a})R^{14b}$, $-C(O)R^{14c}$, $-C(O)OR^{14d}$, $-C(O)N(R^{14e})R^{14f}$, $-N(R^{14g})C(O)R^{14h}$,
 $-N(R^{14i})C(O)N(R^{14j})R^{14k}$, $-N(R^{14m})S(O)_2R^{13b}$, $-S(O)_2R^{13c}$ and/or
 $-OS(O)_2R^{13d}$;

 R^7 represents H, C_{1-6} alkyl, -E-aryl, -E-Het¹, $-C(O)R^{9a}$, $-C(O)OR^{9b}$,

15 $-S(O)_2R^{9c}$, $-[C(O)]_pN(R^{10a})R^{10b}$ or $-C(NH)NH_2$;

 R^{9a} to R^{9d} independently represent, at each occurrence when used herein, C_{1-6} alkyl (optionally substituted and/or terminated by one or more substituents selected from halo, aryl and Het²), aryl, Het³, or R^{9a} and R^{9d} independently represent H;

20 R^{10a} and R^{10b} independently represent, at each occurrence when used herein, H or C_{1-6} alkyl
25 (optionally substituted and/or terminated by one or more substituents selected from halo, aryl and Het⁴), aryl, Het⁵, or together represent C_{3-6} alkylene, optionally interrupted by an O atom;
E represents, at each occurrence when used herein, a direct bond or

 C_{1-4} alkylene;

B represents $-Z-$, $-Z-N(R^{12})-$, $-N(R^{12})-Z-$, $-Z-S(O)_n-$ or $-Z-O-$ (in which latter two groups, Z is
25 attached to the carbon atom bearing R^3 and R^4);

Z represents a direct bond or C_{1-4} alkylene; R^{11} and R^{12} independently represent H or C_{1-6} alkyl; R^{13a} to R^{13d} independently represent C_{1-6} alkyl;

100854

- 19 -

R^{14a} and R^{14b} independently represent H, C₁₋₆ alkyl or together represent C₃₋₆ alkylene, resulting in a four- to seven-membered nitrogen-containing ring;

R^{14c} to R^{14m} independently represent H or C₁₋₆ alkyl; and

n represents 0, 1 or 2;

5 p represents 1 or 2;


Het¹ to Het⁵ independently represent, at each occurrence when used herein, five- to twelve-membered heterocyclic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, which heterocyclic groups are optionally substituted by one or more substituents selected from =O, -OH, cyano, halo, nitro, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl, aryloxy, -

10 $N(R^{15a})R^{15b}$, -C(O)R^{15c}, -C(O)OR^{15d}, -C(O)N(R^{15e})R^{15f}, -N(R^{15g})C(O)R^{15h} and -N(R¹⁵ⁱ)S(O)₂R^{15j};


R^{15a} to R^{15j} independently represent C₁₋₆ alkyl, aryl or R^{15a} to R^{15i} independently represent H; and R^2 represents C₁₋₆ alkyl (optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro and aryl) or aryl, wherein each aryl and

15 aryloxy group, unless otherwise specified, is optionally substituted.

wherein a salt of a compound of Formula I



20 in which R^2 is as previously defined is reacted with a compound of Formula III



wherein Y represents O or N(R⁷) and R^4 , R^5 , R^7 and B are as hereinbefore defined, at a temperature in the range of 0°C to 100°C for example at elevated temperature (e.g. 60°C to reflux) in the presence of a water and in the presence of a base.

25

7. A process according to claim 6 in which the salt has been previously isolated in solid form.

100854

- 20 -

8. A process according to either claim 6 or claim 7 for the preparation of *tert*-butyl 2-{7-[(2*S*)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diaza-bicyclo[3.3.1]-non-3-yl}ethylcarbamate which comprises reacting a salt of [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester with 4-[(2*S*)-oxiranylmethoxy]benzonitrile at a temperature in the range of 0°C to 100°C in the presence of water and in the presence of a base.

9. A process according to any one of claims 6, 7 or 8 in which an isolated salt of [2-(9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)-ethyl]-carbamic acid *tert*-butyl ester is used.

10

10. A process according to either claim 9 wherein the salt is the 2,4,6-trimethylbenzenesulfonic acid salt.

15


100854

- 21 -

ABSTRACT

Title : Chemical Intermediate

An acid addition salt of a compound of Formula I



wherein R² represents C₁₋₆ alkyl (optionally substituted and/or terminated by one or more substituents selected from -OH, halo, cyano, nitro and aryl) or aryl, wherein each aryl and 10 aryloxy group, unless otherwise specified, is optionally substituted.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.